FLT1 and neoplasm: Mechanisms of tumor resistance towards bevacizumab include increased VEGFR-1 expression (in tumor, endothelial cells and monocytes/macrophages) and signaling and/or up-regulation of the VEGFR-1 specific ligand PlGF [39–41].